Alan J. Biloski, Ph.D.

Brock Capital

Alan Biloski works with high-quality pharmaceutical and biotech companies, and their major investors, to optimize business and financial strategies. His multi-disciplinary 30+ year career in the healthcare field – with experience as a scientist, a big pharma employee, a venture capitalist and an investment banker – enables him to rapidly bring forward practical and actionable ideas to help clients achieve the best possible valuation.

Dr. Biloski has led the seed round financings of a number of life science start-up companies in a diverse array of fields ranging from big data/AI (GNS Healthcare) to biotech (Advanced Medicine) and pharmaceutical services (Advion). As the lead pharma and biotech partner at Brock Capital, Dr. Biloski works with the independent fiduciary and family office groups to focus Brock Capital’s Opportunity Fund on the evaluation of direct investments in promising new companies.

Dr. Biloski’s prior experience includes 11 years of service as Senior Lecturer on the faculty of the Samuel Curtis Johnson Graduate School of Management at Cornell University where he led the Investment Banking Immersion and supported the practicums for the Research, Sales and Trading and Managerial Finance Immersions. While there, his students secured over 250 first tier investment banking jobs on Wall Street.

After a 15-year career in M&A banking, Dr. Biloski retired as Managing Director of Merrill Lynch in April 2001. He had joined the firm’s Healthcare Group in July 1998 and advised clients on approximately $100 billion of M&A transactions, including Pfizer’s unsolicited bid for Warner Lambert, MedImmune’s acquisition of US Bioscience, the sale of Mycogen to Dow Chemical and Alkermes acquisition of Advanced Inhalation Research. In November 2000, he advised Immunex on a comprehensive restructuring that included major governance changes, the dilution of AHP’s ownership interest in Immunex from 55% to 41% and the largest biotech equity offering in history with the sale of $3.2 billion in Immunex common stock. He also led efforts that produced two of the largest private placements in biotech history, raising $160 million for Advanced Medicine (now Theravance) in 1999 and $110 million for Eyetech in 2000.

As founder of the Healthcare Group at Wasserstein Perella & Co. in 1991, Dr. Biloski assembled a group of 12 professionals who concluded over $40 billion in pharmaceutical, health service, and medical device deals. Through his specialization in pharmaceuticals, Dr. Biloski has been responsible for a number of landmark transactions such as SmithKline Beecham’s acquisition of Sterling Winthrop (largest OTC deal), the sale of Sterling Winthrop North American to Bayer (second largest OTC deal), the sale of SmithKline Beecham’s animal health business to Pfizer (largest animal health deal), SmithKline Beecham’s purchase of DPS from United Healthcare (third largest pharmacy benefits manager deal), and the Chapter 11 reorganization of A.H. Robins (largest pharmaceutical product liability and bankruptcy).

Dr. Biloski is also an alumnus of the Healthcare Mergers and Acquisitions Group at the First Boston Corporation. While there he assisted senior bankers in over $10 billion in healthcare M&A transactions including the sale of A. H. Robins to American Home Products, the sale of Lyphomed to Fujisawa Pharmaceuticals, Bayer AG’s purchase of Cooper Technicon and SmithKline Beecham’s acquisition of International Clinical Laboratories.

He has experience as a venture capitalist, through the Princeton, NJ firm of Johnston Associates, and as a strategic planner with Merck Sharp and Dohme Research Laboratories. Dr. Biloski also served on the Board of Directors of Merrill Lynch Ventures where he had primary responsibility for evaluating new investments in the health care field. Dr. Biloski has assisted early stage life science companies in financing their businesses, raising $15 million for Advion through Skyline and Perseus-Soros and $5.5 million for Gene Network Sciences (now ViaScience). In addition, he assists management in strategic transactions such as advising Adolor in structuring an alliance with Glaxo for the codevelopment and co-marketing of Alvimopan, advising Eyetech in structuring an alliance with Pfizer for the co-development and co-marketing of Macugen, advising Sagres Discovery in a merger with Chiron and Spectral Genomics in an asset sale to Perkin Elmer.

In 2004 Dr. Biloski was elected to the Board of Directors of the Boyce Thompson Institute (, one of the world’s leading independent institutions for plant research. From 2005-2011 Dr. Biloski served as Vice Chairman of the Board of Directors and chaired the BTI Investment Committee which is charged with managing the Institutes ~$100 MM endowment and since that time he has transitioned to head the Finance Committee. He holds a Ph.D. in synthetic organic chemistry from Cornell University and a M.B.A. with distinction from Columbia University. He was elected to Phi Beta Kappa at Yale University and graduated summa cum laude with a B.S./M.S. in Chemistry.